Cara’s chronic pain drug data disappoints, shares plunge
(Adds details; Updates shares) June 29 (Reuters) – Cara Therapeutics Inc reported disappointing data from a key study testing its chronic pain treatment in patients with osteoarthritis, sending the drug developer’s shares down about 32 percent after the bell on Thursday. The company was testing three dosages of its…